SCHEMBL11028024

SCHEMBL11028024

COc1ccccc1NC(=O)n1cc[c]n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.53
MAPK1 P28482 1/20 0.53
KDM4E B2RXH2 3/20 0.51
TDP1 Q9NUW8 1/20 0.51
SMN1; SMN2 Q16637 5/20 0.49
MAPT P10636 3/20 0.49
TP53 P04637 1/20 0.49
ALDH1A1 P00352 5/20 0.48
POLB P06746 1/20 0.47
HTT P42858 2/20 0.47
TSHR P16473 2/20 0.46
USP2 O75604 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CASP3 P42574 1/20 0.46
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
ALOX15 P16050 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28275012 0.72 KDM4E (0.88) PKMMAPK1KDM4ETDP1SMN1; SMN2
SCHEMBL31040567 0.70 POLB (0.77) KDM4ESMN1; SMN2MAPTALDH1A1POLB
SCHEMBL4554983 0.70 POLB (0.77) KDM4ESMN1; SMN2MAPTALDH1A1POLB
SCHEMBL6850954 0.70 ALDH1A1 (0.71) PKMMAPK1KDM4ETDP1SMN1; SMN2
SCHEMBL9322066 0.69 CASP3 (0.57) PKMMAPK1KDM4ETDP1SMN1; SMN2
SCHEMBL514089 0.69 KMT2A (0.68) PKMMAPK1TDP1SMN1; SMN2MAPT
SCHEMBL171580 0.69 KMT2A (0.70) PKMMAPK1KDM4ETDP1SMN1; SMN2
SCHEMBL2755842 0.69 ALDH1A1 (0.77) PKMMAPK1SMN1; SMN2MAPTALDH1A1
SCHEMBL2093160 0.69 ALDH1A1 (0.62) PKMMAPK1TDP1SMN1; SMN2MAPT
SCHEMBL30356246 0.69 KMT2A (0.70) PKMMAPK1KDM4ETDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP claimed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US claimed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD PKM 652/4885MAPK1 281/4885KDM4E 1665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.